Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOX-D2: S-1 plus oxaliplatin followed by D2 gastrectomy in HER2-negative gastric cancer with extensive lymph node metastasis
jRCTs051180198Phase 2Active, not recruiting
- Start
- May 2018
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tegafur and oxaliplatin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma. Primary endpoint: 3-year overall survival. Started May 2018; status: active, not recruiting.
02
Drugs
tegafuroxaliplatin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCTs051180198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180198.